NCT00936819 - The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 19, 2013

Primary Completion Date

March 5, 2020

Study Completion Date

November 30, 2029

Conditions

Anterior Wall Myocardial Infarction

Interventions

BIOLOGICAL

Plasma-Lyte A and 25% Autologous Plasma

Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery

BIOLOGICAL

Autologous EPCs

Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery

BIOLOGICAL

Autologous EPCs Transfected with human eNOS

Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery

Trial Locations (3)

University of Ottawa Heart Institute, Ottawa

St. Michael's Hospital, Toronto

L'institut de cardiologie de Montreal, Montreal